Document Detail

Erythropoietin as a neuroprotective agent.
MedLine Citation:
PMID:  21402522     Owner:  NLM     Status:  In-Data-Review    
NEONATAL NURSES ARE most familiar with recombinant er y thropoietin (EPO), epoetin alfa (Epogen, Amgen Manufacturing, Thousand Oaks, California; Procrit, Amgen, Inc., Thousand Oaks, California, for Centocor Ortho Biotech Products, LP, Raritan, New Jersey), a treatment for anemia of prematurity. Recent animal and human neonatal studies demonstrate the potential for a neuroprotective function of EPO in infants with hypoxicischemic encephalopathy (HIE).1-3 Erythropoietin has also been shown to improve functional and histologic outcome in neonatal stroke in an animal model.4 Finally, in a study of 16 premature infants, researchers found that infants with elevated EPO concentrations had higher Mental Development Index scores than those with lower EPO concentrations.5 This column discusses the physiology of EPO and describes its neuroprotective pharmacology through an exploration of the related research.
Susan Givens Bell
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Neonatal network : NN     Volume:  30     ISSN:  1539-2880     ISO Abbreviation:  Neonatal Netw     Publication Date:    2011 Mar-Apr
Date Detail:
Created Date:  2011-03-15     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8503921     Medline TA:  Neonatal Netw     Country:  United States    
Other Details:
Languages:  eng     Pagination:  135-9     Citation Subset:  N    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A rare cause of early neonatal death and pathologic examination of the placenta.
Next Document:  Screening cold-acclimation differential expression candidate genes in the brain of common carp (Cypr...